Quisette P Janssen
Erasmus University Rotterdam
Internal medicineRadiologyOncologyRandomized controlled trialClinical endpointChemotherapyPerformance statusNeutropeniaFOLFIRINOXPerineural invasionAdjuvantStandard treatmentAdjuvant therapyResection marginNeoadjuvant therapyChemotherapy regimenChemoradiotherapyPancreatectomyPasireotideMEDLINEFolinic acidSurgical oncologyPancreatic cancerGemcitabineIrinotecanProgression-free survivalPancreatic fistulaOxaliplatinRegimenFolfirinox RegimenMetastatic pancreatic cancerHistorical CohortBorderline resectableIn patientNeoadjuvant chemoradiotherapyAdjuvant chemotherapyLocally advanced pancreatic cancerPan europeanConfidence intervalRadiation therapyGeneral surgeryText miningMedicineCohortAdded valueGastroenterologyMeta-analysis
13Publications
3H-index
105Citations
Publications 14
Newest
#1Fleur van der Sijde (EUR: Erasmus University Rotterdam)H-Index: 3
#2Zakia Azmani (EUR: Erasmus University Rotterdam)
Last. Quisette P Janssen (EUR: Erasmus University Rotterdam)H-Index: 3
view all 0 authors...
Background:Biomarkers predicting treatment response may be used to stratify pancreatic ductal adenocarcinoma (PDAC) patients for therapy. The aim of this study was to identify circulating tumor DNA...
Source
#1Quisette P Janssen (EUR: Erasmus University Rotterdam)H-Index: 3
#2Jacob L. van Dam (EUR: Erasmus University Rotterdam)H-Index: 3
Last. Alice C. Wei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
view all 14 authors...
Source
#1Quisette P Janssen (EUR: Erasmus University Rotterdam)H-Index: 3
#2Jacob L. van Dam (EUR: Erasmus University Rotterdam)H-Index: 3
Last. Alice C. Wei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
view all 14 authors...
BACKGROUND The added value of radiotherapy following neoadjuvant FOLFIRINOX chemotherapy in patients with resectable or borderline resectable pancreatic cancer ((B)RPC) is unclear. The objective of this meta-analysis was to compare outcomes of patients who received neoadjuvant FOLFIRINOX alone or combined with radiotherapy. METHODS A systematic literature search was performed in Embase, Medline (ovidSP), Web of Science, Scopus, Cochrane, and Google Scholar. The primary endpoint was pooled median...
1 CitationsSource
Source
#1Quisette P Janssen (EUR: Erasmus University Rotterdam)H-Index: 3
#2J.L. van Dam (EUR: Erasmus University Rotterdam)
Last. B. Groot Koerkamp (EUR: Erasmus University Rotterdam)H-Index: 2
view all 21 authors...
BACKGROUND Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regim...
7 CitationsSource
#1Quisette P JanssenH-Index: 3
#2M.G.H. BesselinkH-Index: 5
Last. B. Groot KoerkampH-Index: 18
view all 6 authors...
Source
#2Quisette P JanssenH-Index: 3
Last. B. Groot KoerkampH-Index: 18
view all 4 authors...
Source
#1Stijn van Roessel (UvA: University of Amsterdam)H-Index: 7
#2Eran van Veldhuisen (UvA: University of Amsterdam)H-Index: 7
Last. Marc G. Besselink (UvA: University of Amsterdam)H-Index: 84
view all 44 authors...
Importance The benefit of adjuvant chemotherapy after resection of pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. Objective To assess the association of adjuvant chemotherapy with overall survival (OS) in patients after pancreatic cancer resection and neoadjuvant FOLFIRINOX treatment. Design, Setting, and Participants This international, multicenter, retrospective cohort study was conducted from ...
16 CitationsSource
#1Quisette P Janssen (EUR: Erasmus University Rotterdam)H-Index: 3
#2Eileen M. O'Reilly (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 73
Last. Bas Groot Koerkamp (EUR: Erasmus University Rotterdam)H-Index: 40
view all 4 authors...
Approximately 20% of pancreatic ductal adenocarcinoma (PDAC) patients have (borderline) resectable pancreatic cancer ((B)RPC) at diagnosis. Upfront resection with adjuvant chemotherapy has long been the standard of care for these patients. However, although surgical quality has improved, still about 50% of patients never receive adjuvant treatment. Therefore, recent developments have focused on a neoadjuvant approach. Directly comparing results from neoadjuvant and adjuvant regimens is challengi...
15 CitationsSource
#1Quisette P JanssenH-Index: 3
#2Marjolein Y.V. HomsH-Index: 17
Last. B. Groot KoerkampH-Index: 18
view all 6 authors...
2 CitationsSource